What We're Reading: Page 241
Industry reads hand-picked by our editors
May 29, 2019
-
STAT
Powerful new cancer drugs can trigger diabetes — and no one knows why
-
Cincinnati Enquirer
Trump pushed for the federal right-to-try law. One year later, only two people got treatment
-
BioCentury
Maryland creates drug affordability review board
-
The Boston Globe
Mass. lawmaker claims Purdue Pharma corrupted World Health Organization
May 28, 2019
-
The Wall Street Journal
Drug Giant Tries New Tactic to Fight Cancer
-
The New York Times
Scientists Wanted: Recruited by Juul, Many Researchers Say No
-
FierceBiotech
Fred Hutchinson team uses gold nanoparticles to improve CRISPR gene editing
-
The Washington Post
There's just one female physician in Congress. We talked to her.
May 24, 2019
-
CNN
Colorado is the first state to cap skyrocketing insulin co-pays
-
The Wall Street Journal
Trump Administration Preparing Executive Order on Health-Cost Disclosure
-
STAT
Powerful senators are taking surprisingly aggressive aim at PBMs
-
Bloomberg
Citi Says Biotech Tide May Turn as Large Deals Are Shunned
May 23, 2019
-
Bloomberg
AstraZeneca Offers a Perch to Cancer High Flier Who Stumbled
-
The Wall Street Journal
NYSE cuts fees to court biotech listings away from Nasdaq
-
The Atlantic
Why anti-vax doctors are ordering 23andMe tests
-
Axios
Former FDA head Scott Gottlieb rejoins venture capital firm New Enterprise Associates
May 22, 2019
-
CNBC
Novartis CEO says cannabis isn’t a focus despite Tilray partnership
-
FiercePharma
Lilly oncology suffers another blow as Verzenio slapped with safety warning in Japan
-
Bloomberg
India's biggest drugmaker plans to start developing its own medicines
-
TechCrunch
Famed founder Daphne Koller tells it straight: "With most drugs, we do not understand why they work"
May 20, 2019
May 17, 2019
-
Institutional Investor
This venture capital fund wants to get you pregnant
-
STAT
Thorny questions on apps matching cancer patients to clinical trials
-
Reuters
Five more U.S. states sue OxyContin maker Purdue Pharma over opioid epidemic
-
C&EN
With several long-acting HIV treatments in the works, the newest drugs emphasize convenience
Previous
